Loader

Pathways

PathWhiz ID Pathway Meta Data

PW176393

Pw176393 View Pathway
metabolic

Methylprednisone Predicted Metabolism Pathway

Homo sapiens
Metabolites of Methylprednisone are predicted with biotransformer.

PW147113

Pw147113 View Pathway
metabolic

Methylscopolamine Drug Metabolism Pathway

Homo sapiens
Gadoversetamide is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Gadoversetamide passes through the liver and is then excreted from the body mainly through the kidney.

PW145751

Pw145751 View Pathway
drug action

Methyltestosterone Drug Metabolism Action Pathway

Homo sapiens

PW132434

Pw132434 View Pathway
metabolic

Methyprylon Drug Metabolism

Homo sapiens
Methyprylon is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Methyprylon passes through the liver and is then excreted from the body mainly through the kidney.

PW145196

Pw145196 View Pathway
drug action

Methyprylon Drug Metabolism Action Pathway

Homo sapiens

PW132589

Pw132589 View Pathway
metabolic

Methysergide Drug Metabolism

Homo sapiens
Methysergide is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Methysergide passes through the liver and is then excreted from the body mainly through the kidney.

PW144376

Pw144376 View Pathway
drug action

Methysergide Drug Metabolism Action Pathway

Homo sapiens

PW128456

Pw128456 View Pathway
drug action

Methysergide Mechanism of Action Action Pathway

Homo sapiens
Methysergide is an ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle. Methysergide is a semisynthetic ergot alkaloid ergometrine derivative, introduced in pharmacotherapy for migraine prophylaxis as a specific serotonin (5HT) receptor antagonist. Methysergide is not just a 5HT2 antagonist, it is also a 5HT1 agonist.

PW000712

Pw000712 View Pathway
drug action

Metiamide Action Pathway

Homo sapiens
Metiamide is a histamine H2-receptor antagonist that can bind and inhibit histamine H2-receptor to prevent the histamine effects on basolateral memrbane in gastric parietal cell. Binding and inhibition of histamine H2-receptor can lead to decreased gastric acid secretion so that lowering gastric volume as well as acidity.

PW124516

Pw124516 View Pathway
drug action

Metiamide H2 Anti-Histamine Action Pathway

Homo sapiens
Metiamide is an histamine H2 receptor antagonist used to treat stomach ulcers and Gastroesophageal Reflux Disease (GERD). After being taken orally, it is absorbed in the GI tract and travels through the blood to get to the stomach epithelium. Ranitidine binds reversibly to the histamine H2 receptor blocking histamine from binding instead. This blocks the downstream Gs cascade which produces cyclic adenosine monophosphate (cAMP) which is an activator for the potassium-hydrogen ATPase pump (H+/K+ ATPase pump). The pump is responsible for secreting hydrogen ions into the stomach lumen increasing the acidity of the stomach environment. By blocking adenylate cyclase signalling pathway from the histamine H2 receptor less hydrogen ions are secreted into the stomach lumen increasing the pH. The less acidic environment doesn't irritate the stomach as much. The H+/K+ ATPase pump can still be activated through gastrin and acetylcholine through the phospholipase C signalling pathway, but blocking the adenylate cyclase pathway helps reduce the acidity.